Experts at UT MD Anderson have numerous presentations throughout the ESMO Congress 2026 program. Note: Times are listed in either CEST (Central European Summer Time) or CET (Central European Time) as noted for each day.
Experts at UT MD Anderson have numerous presentations throughout the ESMO Congress 2026 program. Note: Times are listed in either CEST (Central European Summer Time) or CET (Central European Time) as noted for each day.
Friday, October 23 (All times are listed in CEST)
Educational session
13:30每15:00 (1:30每3 p.m.) 岫Cordoba Auditorium 〞 Hall 4
Validating AI for oncology: Navigating the road to clinical implementation
14:30每14:45 (2:30每2:45 p.m.)
Presenter:
Young oncologist session
13:30每14:30 (1:30每2:30 p.m.) 岫Toledo Auditorium 〞 NCC
Early-phase clinical trials
Presenter:
Rapid oral session
16:15每17:45 (4:15每5:45 p.m.) 岫Barcelona Auditorium 〞 Hall 9
Abstract 540RO: Ultrasensitive monitoring of early ctDNA dynamics during neoadjuvant treatment in early-stage triple-negative breast cancer: Pre-interim results from the B-STRONGER-I study
Presenter:
Special symposium
16:15每17:45 (4:15每5:45 p.m.) 岫Burgos Auditorium 〞 Hall 3
Chair: Ana Aparicio, M.D.
New targets (ADCs, new biologies)
17:15每17:35 (5:15每5:35 p.m.)
Presenter:
Saturday, October 24 (All times are listed in CEST)
Rapid oral session
08:30每10:00 (8:30每10 a.m.) 岫Murcia Auditorium 〞 Hall 3
Abstract 1245RO: Updated results from FONTANA: Torvutatug samrotecan (torvu-sam), a folate receptor 汐 (FR汐)-targeted antibody-drug conjugate (ADC), in patients (pts) with platinum-resistant ovarian cancer (PROC)
Presenter:
Educational session
08:30每10:00 (8:30每10 a.m.) 岫Madrid Auditorium 〞 Hall 4
Logistics of cellular therapy
09:10每09:30 (9:10每9:30 a.m.)
Presenter:
Educational session
16:30每18:00 (4:30每6 p.m.) 岫Malaga Auditorium 〞 Hall 3
Current treatment landscape of AML based on a comprehensive genomic assessment
16:30每16:50 (4:30每4:50 p.m.)
Presenter:
Sunday, October 25 (All times are listed in CET)
Rapid oral session
8:30每10:00 (8:30每10 a.m.) 岫 Leon Auditorium 〞 Hall 4
Abstract 4244RO: NeoCOAST-2: Association of ctDNA clearance with clinical outcomes in a global platform Phase 2 perioperative trial
Presenter:
Rapid oral session
8:30每10:00 (8:30每10 a.m.) 岫Cordoba Auditorium 〞 Hall 4
Abstract 1006RO: Phase 1 study of FMC-376, a KRAS G12C equipotent ON+OFF inhibitor in pts with advanced KRAS G12C mutant solid tumors
Presenter:
Multidisciplinary session
14:45每16:00 (2:45每4 p.m.) 岫Leon Auditorium 〞 Hall 4
Pathological response for the win
15:30每15:50 (3:30每3:50 p.m.)
Presenter:
Proffered paper session
14:45每16:25 (2:45每4:25 p.m.) 岫Seville Auditorium 〞 NCC
Abstract 3438O: Safety and immunogenicity of re-vaccination with Nous-209: A neoantigen vaccine for cancer interception in Lynch syndrome carriers
Presenter:
Monday, October 26 (All times are listed in CET)
Special symposium
08:30每10:00 (8:30每10 a.m.) 岫Leon Auditorium 〞 Hall 4
Chair: Timothy Yap, M.B.B.S., Ph.D.
New small molecules
09:15每09:30 (9:15每9:30 a.m.)
Presenter:
Educational session
10:15每11:45 (10:15每11:45 a.m.) 岫Almeria Auditorium 〞 Hall 9
Biology and mechanisms of action of novel immunotherapies
10:35每10:55 (10:35每10:55 a.m.)
Presenter:
Special symposium
14:45每16:15 (2:45每4:15 p.m.) 岫Leon Auditorium 〞 Hall 4
Chair:
Bispecific antibodies
14:45每15:00 (2:45每3 p.m.)
Presenter:
Rapid oral session
14:45每16:15 (2:45每4:15 p.m.) 岫 Salamanca Auditorium 〞 Hall 10
Abstract 1153RO: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment): A pilot randomized trial
Presenter: N迆ria Agust赤, M.D.
Special symposium
16:30每18:00 (4:30每6 p.m.) 岫Granada Auditorium 〞 Hall 4
IO-based systemic therapy (including patient selection)
16:30每16:45 (4:30每4:45 p.m.)
Presenter:
Posters (All are in the Poster Area in Hall 5)
Friday, October 23 (All times are listed in CEST)
15:15每16:00 (3:15每4 p.m.)
Developmental therapeutics
Abstract 1010P: Analysis of the safety, tolerability and PK of EIK1005, a novel WRN inhibitor
Presenter: Timothy Yap, M.B.B.S., Ph.D.
Abstract 1014P: ESPERANZA: Results from an external comparator study of trastuzumab deruxtecan in HER2 IHC3+ solid tumors
Presenter: Funda Meric-Bernstam, M.D.
Abstract 1018P: Phase 1 dose-escalation trial of novel TROP2-targeted antibody drug conjugate OBI-992 in patients with advanced solid tumors
Presenter: Apostolia Maria Tsimberido, MD., Ph.D.
Abstract 1025P: Phase 1a clinical trial of TTX-MC138, a first-in-class antagomir against advanced solid tumors
Presenter: Siqing Fu, M.D., Ph.D.
Abstract 1043P: First-in-human trial of BGB-58067, an MTA-cooperative PRMT5 inhibitor, in MTAP-deficient advanced tumors
Presenter: Jordi Rodon Ahnert, M.D., Ph.D.
Abstract 1057P: Tambotatug pelitecan (YL201): Analyses of interstitial lung disease in patients with advanced solid tumours from Phase 1/2 studies
Presenter: Siqing Fu, M.D., Ph.D.
Abstract 1072P: Safety and activity of IAM1363, a CNS penetrant HER2 TKI in participants with HER2-altered advanced cancers
Presenter: Ecaterina Dumbrava, M.D.
Abstract 1082TiP: Trial in Progress: Part 2 cohort expansion of a Phase 1 study of PLN-101095, a dual 汐v汕8/汐v汕1 integrin inhibitor, in combination with pembrolizumab in immune checkpoint inhibitor-refractory advanced solid tumors
Presenter: Timothy Yap, M.B.B.S., Ph.D.
Translational research and biomarkers
Abstract 4403P: Clonal and subclonal resistance during anti-EGFR rechallenge in metastatic colorectal cancer
Presenter: Guglielmo Vetere, M.D.
Abstract 4440P: Goblet cell appendiceal adenocarcinoma is a distinct disease entity defined by LGR5/Wnt mediated oncogenesis driving an immune-excluded tumor microenvironment
Presenter: John Paul Shen, M.D.
Abstract 4445P: Prevalence, prognosis, and impact on tumor microenvironment (TME) of homozygous MTAP deletion (MTAP-del) in advanced solid tumors
Presenter: Jordi Rodon Ahnert, M.D., Ph.D.
Abstract 4260P: Clinical utility of reflex liquid comprehensive genomic profiling (LCGP) to complement tumor-informed circulating tumor DNA (ctDNA) monitoring in solid tumors
Presenter: Jason Mouabbi, M.D.
Abstract 4264P: Evaluation of ctDNA minimal residual disease (MRD) testing to complement radiographic surveillance in patients (Pts) with colorectal cancer (CRC): Results from the MD Anderson (MDA) INTERCEPT program
Presenter: Arvind Dasari, M.D.
Saturday, October 24 (All times are listed in CEST)
12:00每12:45 (12每12:45 p.m.)
Investigational immunotherapy
Abstract 1967P: COVID mRNA vaccines before immune checkpoint inhibitors: A target trial emulation and external validation cohort
Presenter: Sage Copling
1971P - Development of clinical benefit and progression-free survival scores for patient selection in early-phase immunotherapy trials
Presenter: Harold Nathan Tan, M.D.
Miscellaneous
Abstract 4863P: RNA?seq phasing spotlights secondary oncogenic mutations for clinical interpretation
Presenter: Neeta Somaiah, M.D.
Non-melanoma skin tumors
Abstract 2490P: A Phase 2 study of neoadjuvant cemiplimab for stage II每IV cutaneous squamous cell carcinoma (CSCC): Final analysis
Presenter: Neil Gross, M.D.
Palliative care
Abstract 3105P: Impact of culture change duration prior to structural intervention on non-beneficial end-of-life (EOL) systemic anti-cancer therapy (SACT)
Presenter: Narmeen Somani
Sunday, October 25 (All times are listed in CET)
12:00每12:45 (12每12:45 p.m.)
AI for clinical research and drug development
Abstract 145P: Agentic large language model for auditable line-of-therapy extraction from unstructured electronic health records in colorectal cancer
Presenter: Cynthia Yeung, M.D.
Colon cancer
Abstract 797P: Overall survival in young- vs average-onset metastatic colorectal cancer across actionable molecular subgroups: A 4,717-patient hierarchical analysis at UT MD Anderson
Presenter: Cynthia Yeung, M.D.
Abstract 828P: Young-onset versus late-onset colorectal cancer in Phase 1 trials: Toxicity and survival outcomes
Presenter: Berta Martin-Cullell, M.D.
Abstract 860P: Organ-speci?c response to KRAS inhibitors in metastatic colorectal cancer
Presenter: Emerik Osterlund, M.D., Ph.D.
Abstract 863P: Chromosomal instability is associated with worse survival and an immunosuppressive tumor microenvironment in microsatellite stable colorectal cancer
Presenter: Paulino Tall車n De Lara, M.D., Ph.D.
Esophagogastric cancer
Abstract 2953P: Immune checkpoint inhibitor e?cacy in resectable microsatellite instability-high gastric or gastroesophageal junction cancer
Presenter: Ryan Morgan, M.D.
Pancreatic cancer
Abstract 3140P: Allele specific characteristics of KRASQ61-mutated gastrointestinal malignancies with clinical outcomes and transcriptomic features in pancreatic cancer
Presenter: Dan Zhao, M.D., Ph.D.
Abstract 3187TiP: A Phase 2 study evaluating navlimetostat (BMS-986504) and chemotherapy in resectable/borderline resectable (cohort 1), locally advanced, unresectable (cohort 2), and metastatic (cohort 3) MTAP-deleted pancreatic cancer
Presenter: Maria Pia Morelli, M.D., Ph.D.
Policy
Abstract 3380P: Stakeholder perspectives on cancer care capacity in Ukraine: Findings from a national needs assessment
Presenter: Darya Kizub, M.D.
Primary Prevention
Abstract 3456P: Survival associated with risk-reducing bilateral mastectomy versus screening in patients with pathogenic variants in BRCA1/2: A network meta-analysis
Presenter: Isabel Beshar, M.D.
Monday, October 26 (All times are listed in CET)
12:00每12:45 (12每12:45 p.m.)
Gynecological cancers
Abstract 1278P: LINNET: A Phase 2 study to evaluate lorigerlimab in participants (pts) with advanced gynecologic cancers
Presenter: Amir Jazaeri, M.D.
Abstract 1293P: Use of bevacizumab for the treatment of minimal residual disease (MRD) positive high-grade epithelial ovarian cancer: A Phase 2 study
Presenter: Amir Jazaeri, M.D.
Hematological malignancies
Abstract 1478P: Clinical prediction model for early mortality in leukemia patients following inpatient chemotherapy
Presenter: Musa Yilmaz, M.D.
Head and neck cancer, excluding thyroid
Abstract 1549P: A Phase 1a/1b trial of FAP-Dox (AVA6000), a fibroblast activation protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with salivary gland cancers
Presenter: Renata Ferrarotto, M.D.
Abstract 1578P: Neoadjuvant and adjuvant tiragolumab plus atezolizumab in PD-L1-positive oral cavity squamous cell carcinoma
Presenter: Luana Guimaraes de Sousa, M.D.
Non-small cell lung cancer, locally advanced
Abstract 2573P: Imneskibart (AU-007) + low-dose SC IL-2 + avelumab: Phase 2 activity in CPI refractory advanced adenocarcinoma NSCLC
Presenter: George Blumenschein, M.D.
Non-small cell lung cancer, metastatic
Abstract 2629P: Molecular dynamics and mechanisms of acquired resistance in NSCLC patients with EGFR PACC mutations treated with firmonertinib
Presenter: Xiuning Le, M.D., Ph.D.
Abstract 2652P: First-line (1L) Olomorasib + chemoimmunotherapy (Chemo-IO) in KRAS G12C-mutant NSCLC: Updated results from the LOXO-RAS-20001 and SUNRAY-01 trials
Presenter: Marcelo Negrao, M.D.
Abstract 2655P: Initial results from Phase 1/2 dose expansion cohorts: SAR445877 in immunotherapy-exposed advanced non-small cell lung cancer
Presenter: Aung Naing, M.D.
Abstract 2712P: SOHO-01: Updated efficacy and safety of sevabertinib in advanced HER2-mutant NSCLC, including first-line patients (pts) and those with active brain metastases
Presenter: Xiuning Le, M.D., Ph.D.
Sarcoma
Abstract 3760P: AXL protein expression by immunohistochemistry in sarcoma subtypes: Implications for antibody-drug conjugate development
Presenter: Carlos Torrado, M.D.
Give Now
Your gift will help make a tremendous difference.
Research Areas
Find out about the four types of research taking place at UT?MD Anderson.
Subscribe
Get the latest information on our cancer breakthroughs.?